CVG:FRA
CSPC Pharmaceutical Group Ltd
0,89 €
arrow_downward
−0,22%(−0,0020) 1 p
30. apr, 22:00:00 GMT +2 · EUR
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse CVG põhistatistika genereerimine…
Ava
0,89 €
Kõrge
0,89 €
Madal
0,89 €
Turu kapit.
96,90 mld
Keskm. maht
101,00
Maht
0,00
52 näd kõrgeim
1,25 €
52 näd madalaim
0,63 €
Töötajate arv
20 tuh
Uudised
Erinevatest veebiallikatest
TipRanks
·
2 päeva eest
CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate
Profiil
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province.
CSPC produces both active pharmaceutical ingredient and formulations. API products include
penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products.
CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP.
CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises.
One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion.
CSPC Pharma is recognized as one of China's “500 Most Valuable Chinese Brands” and “Top 500 Chinese Enterprises.” Wikipedia
Teave üksuse CSPC Pharmaceutical Group Ltd kohta
AI genereeritud sisu võib sisaldada vigu. Lisateave